Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Age 18-64 Years”

37 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 37 results

Testing effectiveness (Phase 2)Study completedNCT01416571
What this trial is testing

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in Adults

Who this might be right for
Influenza
GlaxoSmithKline 78
Large-scale testing (Phase 3)Study completedNCT01712984
What this trial is testing

Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years

Who this might be right for
Influenza
Sanofi Pasteur, a Sanofi Company 3,360
Testing effectiveness (Phase 2)WithdrawnNCT01008956
What this trial is testing

Safety and Immune Response of One-Dose of Candidate H1N1 Influenza Vaccine GSK2340274A in Adults

Who this might be right for
Influenza
GlaxoSmithKline
Early research (Phase 1)Study completedNCT01659086
What this trial is testing

Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age

Who this might be right for
Influenza
GlaxoSmithKline 422
Testing effectiveness (Phase 2)Study completedNCT04420221
What this trial is testing

Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine (GSK3878858A) When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 64 Years of Age With a Recent S. Aureus Skin and Soft Tissue Infection (SSTI)

Who this might be right for
Infections, Soft Tissue
GlaxoSmithKline 226
Large-scale testing (Phase 3)Study completedNCT05696080
What this trial is testing

Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)

Who this might be right for
Pneumococcal Infection
Merck Sharp & Dohme LLC 518
Testing effectiveness (Phase 2)Study completedNCT00771615
What this trial is testing

Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years

Who this might be right for
Influenza
GlaxoSmithKline 469
Post-approval studies (Phase 4)Study completedNCT03598439
What this trial is testing

Randomized Influenza Vaccine Evaluation of Immune Response

Who this might be right for
Influenza
Marshfield Clinic Research Foundation 366
Post-approval studies (Phase 4)Study completedNCT06518577
What this trial is testing

Immunogenicity of Influenza Vaccinations

Who this might be right for
Influenza
Duke University 605
Large-scale testing (Phase 3)Study completedNCT05310084
What this trial is testing

Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age

Who this might be right for
SARS-CoV-2 InfectionCOVID-19
BioNTech SE 1,134
Early research (Phase 1)Study completedNCT05272605
What this trial is testing

Safety and Immune Response of Adjuvanted SARS-CoV-2 (COVID-19) Beta Variant RBD Recombinant Protein (DoCo-Pro-RBD-1 + MF59®) and mRNA (MIPSCo-mRNA-RBD-1) Vaccines in Healthy Adults

Who this might be right for
SARS-CoV-2
University of Melbourne 76
Testing effectiveness (Phase 2)Study completedNCT05975840
What this trial is testing

Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Astrakhan/3212/2020 Like (H5N8) Virus Vaccine With AS03 Adjuvant System in Medically Stable Adults

Who this might be right for
Influenza, Human
GlaxoSmithKline 518
Testing effectiveness (Phase 2)Looking for participantsNCT06702449
What this trial is testing

A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age

Who this might be right for
Urinary Tract Infections
GlaxoSmithKline 448
Large-scale testing (Phase 3)Study completedNCT01389479
What this trial is testing

Study to Evaluate the Safety, Tolerance and Immunogenicity of Fluviral™ in Healthy Adults

Who this might be right for
Influenza
GlaxoSmithKline 1,000
Not applicableStudy completedNCT00791453
What this trial is testing

Clarksdale Diabetes and Metabolism Clinic CHEC Study

Who this might be right for
Diabetes
University of Mississippi Medical Center 55
Testing effectiveness (Phase 2)Study completedNCT01011049
What this trial is testing

Study of Influenza Vaccine Revaccination in Healthy Adults Previously Vaccinated With Fluzone ID or Fluzone IM

Who this might be right for
Influenza
Sanofi Pasteur, a Sanofi Company 1,250
Large-scale testing (Phase 3)Study completedNCT00192192
What this trial is testing

Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy Adults

Who this might be right for
Influenza
MedImmune LLC 20
Large-scale testing (Phase 3)Study completedNCT03301051
What this trial is testing

Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults

Who this might be right for
Virus DiseasesRNA Virus InfectionsRespiratory Tract Diseases+2 more
Medicago 10,160
Not applicableStudy completedNCT04664699
What this trial is testing

Randomized Control Trial to Compare Standard Monitoring and Plethysmographic Variability Index-Guided Fluid Therapy In 64 Severe Traumatic Brain Injury Patients, Aged 18 to 60 Years Old Undergoing Emergency Craniotomies

Who this might be right for
Severe Traumatic Brain Injury
Universiti Sains Malaysia 64
Post-approval studies (Phase 4)Ended earlyNCT05514002
What this trial is testing

Comparison of Recombinant Influenza Vaccine Versus Standard Egg-Based Inactivated Influenza Vaccine in Adults 18-64 Years

Who this might be right for
Influenza, Human
Fatimah Dawood 3,988
Load More Results